You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 8,722,650

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,722,650 protect, and when does it expire?

Patent 8,722,650 protects SOLODYN and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,722,650

Title:	Extended-release minocycline dosage forms
Abstract:	An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Inventor(s):	Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Scottsdale, AZ), Newhard; Steven B. (Scottsdale, AZ), Watt; David (Scottsdale, AZ)
Assignee:	Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:	12/861,424
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,722,650

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-008	Aug 27, 2010		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ACNE	⤷ Sign Up
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-007	Aug 27, 2010		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ACNE	⤷ Sign Up
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-006	Aug 27, 2010		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ACNE	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,722,650

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	⤷ Sign Up
Canada	2613273	⤷ Sign Up
China	101208097	⤷ Sign Up
European Patent Office	1898925	⤷ Sign Up
Japan	2008543936	⤷ Sign Up
Japan	2013213047	⤷ Sign Up
Japan	5744976	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.